amide/癲癇性発作

FIELD OF THE INVENTION The present invention relates to 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, which is a compound of formula ##STR00002## and to pharmaceutically acceptable acid addition salts thereof. This compound is generically

FIELD OF THE INVENTION This invention provides aromatic amides which are useful CNS agents, especially for treating depression, pain, anxiety, schizophrenia and seizure disorders. BACKGROUND OF THE INVENTION Disorders of the central nervous system have become one of the most common and most

TECHNICAL FIELD The present invention relates to alkynyl amides, to the use of these compounds to treat seizures, migraine, and psychiatric disorders, and to the preparation of these compounds. BACKGROUND OF THE INVENTION Epilepsy affects roughly 1% of the world's population. Among the drugs

This invention is concerned with new chemicals which have valuable pharmacological properties. In particular, the invention concerns novel cinnamamides, their synthesis, pharmaceutical preparations containing them, and their use in medicine. It has been found that the cinnamamides of formula (I), as

FIELD OF THE INVENTION The subject invention relates to the use of gamma-aminobutyric acid (GABA) analogs and, more specifically, to the treatment of spastic disorders, convulsions, and epilepsy by administering gamma-aminobutyramide and/or any drug or compound which is broken down to yield

BACKGROUND Potassium (K.sup.+) channels, present on the plasma membranes of most cell types, are the most diverse class of all ion channels and are associated with a wide range of physiological functions including the regulation of the electrical properties of excitable cells. The primary

BACKGROUND Potassium (K.sup.+) channels, present on the plasma membranes of most cell types, are the most diverse class of all ion channels and are associated with a wide range of physiological functions including the regulation of the electrical properties of excitable cells. The primary

BACKGROUND Potassium (K+) channels, present on the plasma membranes of most cell types, are the most diverse class of all ion channels and are associated with a wide range of physiological functions including the regulation of the electrical properties of excitable cells. The primary pore-forming

FIELD OF THE INVENTION This invention concerns novel compounds that activate or otherwise modulate voltage-gated potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders which are affected by modulation of potassium ion channels. One such condition is

BACKGROUND OF THE INVENTION The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active

BACKGROUND OF THE INVENTION This invention relates to certain novel 5-phenyl-2-furan esters and amides and the novel use of these and related compounds as antiepileptic agents. Antiepileptic agents are used to treat seizure disorders. Approximately 2.5 million of all Americans have epilepsy.

BACKGROUND OF THE INVENTION The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to novel imidazolone derivatives which selectively bind to GABAa receptors. More specifically it relates to substituted aryl and cycloalkyl imidazolones and to pharmaceutical compositions comprising such compounds. It

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to novel imidazolone derivatives which selectively bind to GABAa receptors. More specifically it relates to substituted aryl and cycloalkyl imidazolones and to pharmaceutical compositions comprising such compounds. It

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to novel imidazolone derivatives which selectively bind to GABAa receptors. More specifically it relates to substituted aryl and cycloalkyl imidazolones and to pharmaceutical compositions comprising such compounds. It